U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Fallopian tube cancer

MedGen UID:
102276
•Concept ID:
C0153579
•
Neoplastic Process
Synonym: Cancer of the fallopian tube
SNOMED CT: Malignant tumor of fallopian tube (363444001)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
•Concept ID:
CN307044
•
Finding
Source: Orphanet
clinical entity without genetic inheritance.
See: This record
Not genetically inherited (Orphanet)
 
Monarch Initiative: MONDO:0002158
Orphanet: ORPHA180242

Definition

A primary or metastatic malignant neoplasm that affects the fallopian tube. Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVFallopian tube cancer
Follow this link to review classifications for Fallopian tube cancer in Orphanet.

Professional guidelines

PubMed

Frontline Maintenance Treatment for Ovarian Cancer.
Elyashiv O, Wong YNS, Ledermann JA
Curr Oncol Rep 2021 Jun 14;23(8):97. doi: 10.1007/s11912-021-01088-w. PMID: 34125335Free PMC Article
Management of Fallopian Tube Cancer.
Rai S, Maheshwari A
Rev Recent Clin Trials 2015;10(4):276-81. doi: 10.2174/1574887110666150923112556. PMID: 26411954
Staging classification for cancer of the ovary, fallopian tube, and peritoneum.
Prat J; FIGO Committee on Gynecologic Oncology
Int J Gynaecol Obstet 2014 Jan;124(1):1-5. Epub 2013 Oct 22 doi: 10.1016/j.ijgo.2013.10.001. PMID: 24219974

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024

Recent clinical studies

Etiology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?
Kotsopoulos J, Narod SA
Int J Cancer 2020 Sep 1;147(5):1245-1251. Epub 2020 Feb 29 doi: 10.1002/ijc.32916. PMID: 32037528
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Diagnosis

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Therapy

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P
N Engl J Med 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21 doi: 10.1056/NEJMoa1810858. PMID: 30345884
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Prognosis

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Lymphadenectomy in Primary Fallopian Tube Cancer is Associated with Improved Survival.
Xiao Y, Liu YX, Li RN, Wei X, Wang QM, Gu QY, Linghu H
J Invest Surg 2022 Jun;35(6):1417-1423. Epub 2022 Mar 28 doi: 10.1080/08941939.2022.2048142. PMID: 35344678
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
Management of Fallopian Tube Cancer.
Rai S, Maheshwari A
Rev Recent Clin Trials 2015;10(4):276-81. doi: 10.2174/1574887110666150923112556. PMID: 26411954
Primary fallopian tube cancer: domestic data and up-to-date review.
Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, Tsui KH, Wen KC, Chen YJ, Chuang CM, Chao HT, Chang WH
Taiwan J Obstet Gynecol 2014 Sep;53(3):287-92. doi: 10.1016/j.tjog.2014.07.003. PMID: 25286779

Clinical prediction guides

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Prevalence of active cytomegalovirus infection at diagnosis of ovarian cancer and during chemotherapy and subsequent changes in cognitive functioning.
Vogel RI, Stenzel AE, Lee H, Hunter-Schlichting D, Wesley E, Uppendahl LD, Geller MA, Nelson HH
BMC Cancer 2023 Nov 3;23(1):1057. doi: 10.1186/s12885-023-11566-y. PMID: 37923995Free PMC Article
Ultrasound characteristics of early-stage high-grade serous ovarian cancer.
Suh-Burgmann E, Brasic N, Jha P, Hung YY, Goldstein RB
Am J Obstet Gynecol 2021 Oct;225(4):409.e1-409.e8. Epub 2021 May 13 doi: 10.1016/j.ajog.2021.04.262. PMID: 33992598
Proteomic Analysis of the Downstream Signaling Network of PARP1.
Zhen Y, Yu Y
Biochemistry 2018 Jan 30;57(4):429-440. Epub 2018 Jan 19 doi: 10.1021/acs.biochem.7b01022. PMID: 29327913Free PMC Article
Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review.
Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK
Gynecol Oncol 2015 Mar;136(3):571-81. Epub 2015 Jan 20 doi: 10.1016/j.ygyno.2015.01.534. PMID: 25615934

Recent systematic reviews

Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Ngoi NY, Syn NL, Goh RM, Goh BC, Huang RY, Soon YY, James E, Cook A, Clamp A, Tan DS
Cochrane Database Syst Rev 2022 Feb 21;2(2):CD012007. doi: 10.1002/14651858.CD012007.pub2. PMID: 35188221Free PMC Article
Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
Cheng A, Li L, Wu M, Lang J
Eur J Surg Oncol 2020 Jan;46(1):139-147. Epub 2019 Sep 5 doi: 10.1016/j.ejso.2019.09.002. PMID: 31521389
Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review.
Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK
Gynecol Oncol 2015 Mar;136(3):571-81. Epub 2015 Jan 20 doi: 10.1016/j.ygyno.2015.01.534. PMID: 25615934
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G, Pectasides D
J Ovarian Res 2014;7:57. Epub 2014 May 19 doi: 10.1186/1757-2215-7-57. PMID: 24864163Free PMC Article
Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review.
Brockbank EC, Harry V, Kolomainen D, Mukhopadhyay D, Sohaib A, Bridges JE, Nobbenhuis MA, Shepherd JH, Ind TE, Barton DP
Eur J Surg Oncol 2013 Aug;39(8):912-7. Epub 2013 May 27 doi: 10.1016/j.ejso.2013.05.007. PMID: 23721765

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2024
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...